

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10526755
	Filing Date		2003-03-10
	First Named Inventor	Keith R. Cromack	
	Art Unit	1616	
	Examiner Name	not yet known	
Attorney Docket Number		065379-0073 (619504US)	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	3929992		1975-12-30	Sehgal, SN	
	2	3993749		1976-11-23	Sehgal, SN	
	3	4316885		1982-02-23	Rakhit, S	
	4	4401653		1983-08-30	Eng, CP	
	5	4650803		1987-03-17	Stella, VJ	
	6	4885171		1989-12-05	Surendra, SN	
	7	4916193		1990-04-10	Tang, RT	
	8	4994071		1991-02-19	MacGregor, DC	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10526755
Filing Date	2003-03-10
First Named Inventor	Keith R. Cromack
Art Unit	1616
Examiner Name	not yet known
Attorney Docket Number	065379-0073 (619504US)

9	5023262		1991-06-11	Caufield, CE	
10	5092877		1992-03-03	Pinchuk, L	
11	5120725		1992-06-09	Kao, W	
12	5120727		1992-06-09	Kao, W	
13	5120642		1992-06-09	Failli, AA	
14	5163952		1992-11-17	Froix, M	
15	5177203		1993-01-05	Failli, AA	
16	5304121		1994-04-19	Sahatjian, R	
17	5447724		1995-09-05	Helmus, MN	
18	5464650		1995-11-07	Berg, EP	
19	5457111		1995-10-10	Luly, JR	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10526755
Filing Date		2003-03-10
First Named Inventor	Keith R. Cromack	
Art Unit	1616	
Examiner Name	not yet known	
Attorney Docket Number	065379-0073 (619504US)	

20	5516781		1996-05-14	Morris, RE	
21	5527337		1996-06-18	Stack	
22	5605696		1997-02-25	Eury,RP	
23	5563146		1996-10-08	Morris, RE	
24	5624411		1997-04-29	Tuch, RJ	
25	5646160		1997-07-08	Morris, RE	
26	5665728		1997-09-09	Morris, RE	
27	5705583		1998-01-06	Bowers, RWJ	
28	6090901		2000-07-18	Bowers, RWJ	
29	6015815		2000-01-18	Mollison, KW	
30	6273913		2001-08-14	Wright, C	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10526755
Filing Date	2003-03-10
First Named Inventor	Keith R. Cromack
Art Unit	1616
Examiner Name	not yet known
Attorney Docket Number	065379-0073 (619504US)

31	6284305	B1	2001-09-04	Ding, N	
32	6358556	B1	2002-03-19	Ding, N.	
33	6413272	B1	2002-07-02	Igaki, K	
34	6419692	B1	2002-07-16	Yang, D	
35	6505764	B2	2003-07-01	Wright, C	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S.PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20030129215	A1	2003-07-10	Mollison, KW	
	2	20050004661	A1	2005-01-06	Lewis, AL	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

**FOREIGN PATENT DOCUMENTS**

Remove

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
-------------------	---------	--------------------------------------	-----------------------------	------------------------	------------------	---	--	----------------

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10526755
Filing Date	2003-03-10
First Named Inventor	Keith R. Cromack
Art Unit	1616
Examiner Name	not yet known
Attorney Docket Number	065379-0073 (619504US)

1	0184162	EP	A2	1986-06-11	Fujisawa Pharmaceutical Co, Ltd.	<input type="checkbox"/>
2	0467606	EP	A1	1992-01-22	American Home Products Corporation	<input type="checkbox"/>
3	92/05179	WO		1992-04-02	American Home Products Corporation	<input type="checkbox"/>
4	01/87372	WO	A1	2001-11-22	Cordis Corporation	<input type="checkbox"/>
5	02/055122	WO	A1	2002-07-18	Biocompatibles Limited	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	Aggarwal, A., D.J. Schneider, B.E. Sobel, and H.L. Dauerman. 2003. Comparison of inflammatory markers in patients with diabetes mellitus versus those without before and after coronary arterial stenting. <i>Am J Cardiol.</i> 92:924-9.	<input type="checkbox"/>
	2	Baker, H., A. Sidorowicz, S.N. Sehgal, and C. Vezina. 1978. Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. <i>J Antibiot (Tokyo).</i> 31:539-45.	<input type="checkbox"/>
	3	Bierer, B.E., S.L. Schreiber, and S.J. Burakoff. 1991. The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation. <i>Eur J Immunol.</i> 21:439-45.	<input type="checkbox"/>
	4	Biondi-Zoccai, G.G., A. Abbate, G. Liuzzo, and L.M. Biasucci. 2003. Atherothrombosis, inflammation, and diabetes. <i>J Am Coll Cardiol.</i> 41:1071-7.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10526755
Filing Date	2003-03-10
First Named Inventor	Keith R. Cromack
Art Unit	1616
Examiner Name	not yet known
Attorney Docket Number	065379-0073 (619504US)

5	Brown, E.J., M.W. Albers, T.B. Shin, K. Ichikawa, C.T. Keith, W.S. Lane, and S.L. Schreiber. 1994. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. <i>Nature</i> . 369:756-8.	<input type="checkbox"/>
6	Bunchman, T.E., and C.A. Brookshire. 1991. Smooth muscle cell proliferation by conditioned media from cyclosporine-treated endothelial cells: a role of endothelin. <i>Transplant Proc.</i> 23:967-8.	<input type="checkbox"/>
7	Carter, A.J., M. Aggarwal, G.A. Kopla, F. Tio, P.S. Tsao, R. Kolata, A.C. Yeung, G. Llanos, J. Dooley, and R. Fajotio. 2004. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. <i>Cardiovasc Res.</i> 63:617-24.	<input type="checkbox"/>
8	Dandona, P., and A. Aljada. 2002. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. <i>Am J Cardiol.</i> 90:27G-33G.	<input type="checkbox"/>
9	Dumont, F.J., M.R. Melino, M.J. Staruch, S.L. Koprak, P.A. Fischer, and N.H. Sigal. 1990. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. <i>J Immunol.</i> 144:1418-24.	<input type="checkbox"/>
10	Fretz, H., M. Albers, A. Gaia, R. Standaert, W. Lane, S. Burakoff, B. Bierer, and S. Schreiber. 1991. Rapamycin and FK506 binding proteins (immunophilins). <i>J. Am. Chem. Soc.</i> 113:1409-1411.	<input type="checkbox"/>
11	Grech, E.D., and D.R. Ramsdale. 2003. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. <i>British Med. J.</i> 326:1259-61.	<input type="checkbox"/>
12	Harding, M.W., A. Galat, D.E. Uehling, and S.L. Schreiber. 1989. A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. <i>Nature</i> . 341:758-60.	<input type="checkbox"/>
13	Hayward, C., D. Yohannes, and S. Danishefsky. 1993. Total synthesis of rapamycin via a novel titanium-mediated aldol macrocyclization reaction. <i>J. Am. Chem. Soc.</i> 115:9345-9346.	<input type="checkbox"/>
14	Helmus, M. 1990. Medical Device Design--A Systems Approach: Central Venous Catheters. In 22nd International Society for the Advancement of Material and Process Engineering Technical Conference.	<input type="checkbox"/>
15	Ji, Q., M. Reimer, and T. El-Shourbagy. 2004. 96-well liquid-liquid extraction liquid chromatography-tandem mass spectrometry method for the quantitative determination of ABT-578 in human blood samples. <i>Journal of Chromatography B.</i> 805:67-75.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10526755
Filing Date	2003-03-10
First Named Inventor	Keith R. Cromack
Art Unit	1616
Examiner Name	not yet known
Attorney Docket Number	065379-0073 (619504US)

16	Kino, T., N. Inamura, F. Sakai, K. Nakahara, T. Goto, M. Okuhara, M. Kohsaka, H. Aoki, and T. Ochiai. 1987. Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc. 19:36-9.	<input type="checkbox"/>
17	Kornowski, R., M.K. Hong, F.O. Tio, O. Bramwell, H. Wu, and M.B. Leon. 1998. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 31:224-30.	<input type="checkbox"/>
18	Martel, R.R., J. Klicius, and S. Galet. 1977. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol. 55:48-51.	<input type="checkbox"/>
19	Morris, R. 1992. Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant. Rev. 6:39-87.	<input type="checkbox"/>
20	Morris, R., and B. Meiser. 1989. Identification of a new pharmacologic action for an old compound. Med. Sci. Res. 17:609.	<input type="checkbox"/>
21	Nicolaou, K., T. Chakraborty, A. Piscopio, N. Minowa, and P. Bertinato. 1993. Total synthesis of rapamycin. J. Am. Chem. Soc. 115:4419-4420.	<input type="checkbox"/>
22	Paiva, N.L., A.L. Demain, and M.F. Roberts. 1991. Incorporation of acetate, propionate, and methionine into rapamycin by Streptomyces hygroscopicus. J Nat Prod. 54:167-77.	<input type="checkbox"/>
23	Roffi, M., and E.J. Topol. 2004. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 25:190-8.	<input type="checkbox"/>
24	Romo, D., S. Meyer, D. Johnson, and S. Schrieber. 1993. Total synthesis of (-)-rapamycin using an Evans-Tishchenko fragment coupling. J. Am. Chem. Soc. 115:7906-7907.	<input type="checkbox"/>
25	Sabatini, D.M., H. Erdjument-Bromage, M. Lui, P. Tempst, and S.H. Snyder. 1994. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 78:35-43.	<input type="checkbox"/>
26	Schwartz, R. 1992. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 19:267-274.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10526755
Filing Date	2003-03-10
First Named Inventor	Keith R. Cromack
Art Unit	1616
Examiner Name	not yet known
Attorney Docket Number	065379-0073 (619504US)

27	Sehgal, S.N., H. Baker, C.P. Eng, K. Singh, and C. Vezina. 1983. Demethoxyrapamycin (AY-24,668), a new antifungal antibiotic. <i>J Antibiot</i> (Tokyo). 36:351-4.	<input type="checkbox"/>
28	Sehgal, S.N., H. Baker, and C. Vezina. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. <i>J Antibiot</i> (Tokyo). 28:727-32.	<input type="checkbox"/>
29	Shichiri, M., Y. Hirata, T. Nakajima, K. Ando, T. Imai, M. Yanagisawa, T. Masaki, and F. Marumo. 1991. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. <i>J Clin Invest</i> . 87:1867-71.	<input type="checkbox"/>
30	Siekierka, J.J., S.H. Hung, M. Poe, C.S. Lin, and N.H. Sigal. 1989. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. <i>Nature</i> . 341:755-7.	<input type="checkbox"/>
31	Suzuki, T., G. Kopla, S. Hayashi, L.R. Bailey, G. Llanos, R. Wilensky, B.D. Klugherz, G. Papandreou, P. Narayan, M.B. Leon, A.C. Yeung, F. Tio, P.S. Tsao, R. Falotico, and A.J. Carter. 2001. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. <i>Circulation</i> . 104:1188-93.	<input type="checkbox"/>
32	Vezina, C., A. Kudelski, and S.N. Sehgal. 1975. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. <i>J Antibiot</i> (Tokyo). 28:721-6.	<input type="checkbox"/>
33	Yamagishi, S., C.C. Hsu, K. Kobayashi, and H. Yamamoto. 1993. Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. <i>Biochem Biophys Res Commun</i> . 191:840-6.	<input type="checkbox"/>
34	Yudkin, J.S., M. Kumari, S.E. Humphries, and V. Mohamed-Ali. 2000. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? <i>Atherosclerosis</i> . 148:209-14.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10526755
Filing Date	2003-03-10
First Named Inventor	Keith R. Cromack
Art Unit	1616
Examiner Name	not yet known
Attorney Docket Number	065379-0073 (619504US)

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	s/Gregory M. Zinkl	Date (YYYY-MM-DD)	2007-01-15
Name/Print	Gregory M. Zinkl, Ph.D.	Registration Number	48,492

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.